Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Chuikyo Split over Drug Lags and Losses, Rapid Introduction Evaluation System
July 13, 2023
- MHLW Certifies Antibiotics Supply Assurance Plans from Meiji, Fujifilm, Otsuka
July 12, 2023
- MHLW Panel OKs 172 More Health Damage Claims for COVID Vaccines
July 12, 2023
- MHLW Presents Plan to Expand Orphan Drug Designation by Clarifying Requirements
July 11, 2023
- Boost PMDA Manpower to Respond to Proposed Orphan Revamp: Panelists
July 11, 2023
- MHLW Proposes Simultaneous Preparation of Drug Development Plans for Adults and Children
July 11, 2023
- MHLW Pharma Regulation Panel Kicks Off, Agrees to Discuss Incentives to Develop Pediatric Drugs
July 11, 2023
- Label Expansions for Jakavi, Soliris Up for MHLW Panel Review on July 24
July 11, 2023
- PMDA US Office to Set Out Solution for Drug Lag, Loss: Agency Chief
July 10, 2023
- Amid High Turnover Rate, JPWA Presses for New System to Support Drug Prices
July 7, 2023
- Industry Stresses Stronger Price Support Rule to Ensure Stable Supplies
July 7, 2023
- Japan Appropriately Reviewing Alzheimer’s Med Lecanemab: Minister
July 7, 2023
- Reflect Societal Values in Pricing of Regenerative Medicines: FIRM
July 7, 2023
- JPMA Pushes Simple Price Maintenance for Innovative Meds; PhRMA, EFPIA in Sync
July 6, 2023
- Discuss Drug Price Revision System That Doesn’t Cause Yakkasa: FPMAJ Chair
July 6, 2023
- Pharma Groups Float New Methods to Evaluate Innovative Drugs for 2024 Reform
July 6, 2023
- Japan, US, Europe Trade Groups Urge Japan to Abolish “Spillover” Re-Pricing
July 6, 2023
- Drug Pricing Rules to Be Applied to Novartis’ Gene Therapy Luxturna
July 6, 2023
- 5 FPMAJ-Affiliated Bodies Petition Expanded Coverage, Eased Criteria for Essential Drug Rule
July 6, 2023
- Hideo Hashimoto Named MOF Budget Examiner for Healthcare
July 5, 2023
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…